Tumor localization by tumor infiltrating lymphocytes labeled with indium-111 in patients with metastatic renal cell carcinoma, melanoma, and colorectal cancer

Cancer Biotherapy and Radiopharmaceuticals

Volumn 12, Issue 2, 1997, Pages 65-71

  Dillman, Robert O ^a   Hurwitz, S Robert ^a   Schiltz, Patric M ^a   Barth, Neil M ^a   Beutel, Linda D ^a   Nayak, Shankar K ^a   O'Connor, Audrey A ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

Indium 111; Renal cell carcinoma; Tumor infiltrating lymphocytes

Indexed keywords

ALPHA2B INTERFERON; CD4 ANTIGEN; CD8 ANTIGEN; CYCLOPHOSPHAMIDE; INDIUM 111; INTERLEUKIN 2;

ADOPTIVE IMMUNOTHERAPY; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY CARCINOMA; MALE; MELANOMA; METASTASIS; PRIORITY JOURNAL; RADIOISOTOPE DISTRIBUTION; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR LOCALIZATION;

EID: 0030858111     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1997.12.65     Document Type: Article

References (13)

1. Topalian SL, Solomon D, Avis FP et al. Immunotherapy of patients with advanced cancer using tumor-infiltrating lymphocytes with recombinant interleukin-2: a pilot study. J Clin Oncol 1988;6:839-853.
2. Rosenberg SA, Packard BS, Aebersold PM et al. Use of tumor infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma; a preliminary report N Engl J Med 1988;319:1676-1680.
3. Dillman RO, Oldham RK, Barth NM et al. Continuous interleukin-2 and tumor-infiltrating lymphocytes as treatment of advanced melanoma. Cancer 1991;68(1):1-8.
4. Rosenberg SA, Yannelli JR, Yang JC et al Treatment of patients with metastatic melanoma with autologous tumor infiltrating lymphocytes and interleukin-2 J Natl Cancer Inst 1994;86:1159-1166
5. Oldham RK, Dillman RO, Yannelli JR et al. Continuous infusion interleukin-2 and tumor-derived activated cells as treatment of advanced solid tumors; a National Biotherapy Study Group trial. Molec Biother 1991;3.68-73.
6. Kradin RL, Kurnick JT, Lazarus DS et al. Tumorinfiltrating lymphocytes and interleukin-2 in treatment of advanced cancer. Lancet 1989;18:577-580.
7. Bukowski RM, Sharfman W, Murthy S et al. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma. Cancer Res 1991;51:4199-4205.
8. Belldegrun A, Pierce W, Kaboo R et al. Interferon-α primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-α as therapy for metastatic renal cell carcinoma. J Urol 1993;150:1384-1390.
9. Hanson JP, Treisman J, LeFever A, Mikolajczak T, Rohloff C, Rausch C. Treatment of metastatic renal cell carcinoma with combination therapy. Proc Am Soc Clin Oncol 1996; 15:264 [abst 695].
10. Fujita K, Ikarashi H, Takakuwa K et al. Prolonged disease-free period in patients with advanced epithelial ovarian cancer after adoptive transfer of tumor-infiltrating lymphocytes. Clin Cancer Res 1995;1:501-507.
11. Ratto GB, Zino P, Mirabelli S et al A randomized trial of adoptive immunotherapy with tumor infiltrating lymphocytes and interleukin-2 versus standard therapy in the postoperative treatment of resected nonsmall cell lung cancer. Cancer 1996:78:244-251.
12. 111 labeled tumor infiltrating lymphocytes in patients with metastatic melanoma, J Clin Oncol 1989,7:250-261.
13. 111 Indium-labeled tumor infiltrating lymphocytes to tumor in patients receiving adoptive immunotherapy. Cancer 1994,73:1731-1737.